Oxford BioDynamics, the biotechnology company, has signed a lease agreement on a new laboratory and office space at Oxford Business Park, which will “significantly expand” its facilities in the UK. The business is developing precision medicine tests for personalised healthcare based on the EpiSwitch 3D genomics platform.

Its new 24,000 sq ft premises will house the growing Oxford BioDynamics UK infrastructure and will also allow the company to operate independent processing lines for commercial test development and product support, biomarker discovery contracts, clinical trial support and internal R&D projects.

“This new lease comes at an exciting time for OBD, following the launch of both our prognostic test for Covid-19 severity and the EpiSwitch Explorer Array Kit. It marks the next important step of the continued roll-out of our expanded strategic focus,” said Dr Jon Burrows, chief executive of Oxford BioDynamics.

“We moved into our current reference laboratory on the Oxford Business Park in 2015 and expanded it in 2018; this new lease reflects the next stage of our growth. We enjoy excellent support from our landlord, Arlington, and the team at the Business Park. We are very happy to be staying with them as we grow.”

Development work on the site is expected to complete in late July 2021. Financial details for the biotechnology company’s new lease were not disclosed.

“We are delighted to continue supporting the successful growth of Oxford BioDynamics,” added Daniel Williams, development director of Arlington. “Signing this new lease at Building 3140 is testament to our customer-focused approach. With our commitment to deliver the highest quality, flexible workspaces within an amenity rich environment, our Life Science community is thriving. We look forward to working with OBD for many more years to come.”